The 36-month beta value for XFOR is also noteworthy at 0.47. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for XFOR is 115.02M, and at present, short sellers hold a 8.24% of that float. The average trading volume of XFOR on March 25, 2025 was 3.70M shares.
XFOR) stock’s latest price update
X4 Pharmaceuticals Inc (NASDAQ: XFOR) has seen a decline in its stock price by -12.95 in relation to its previous close of 0.29. However, the company has experienced a -12.83% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-25 that Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or 4Q 2025; top-line data anticipated in 2H 2026
XFOR’s Market Performance
X4 Pharmaceuticals Inc (XFOR) has seen a -12.83% fall in stock performance for the week, with a -43.41% decline in the past month and a -57.71% plunge in the past quarter. The volatility ratio for the week is 7.45%, and the volatility levels for the past 30 days are at 10.30% for XFOR. The simple moving average for the past 20 days is -23.18% for XFOR’s stock, with a -57.38% simple moving average for the past 200 days.
Analysts’ Opinion of XFOR
Many brokerage firms have already submitted their reports for XFOR stocks, with B. Riley Securities repeating the rating for XFOR by listing it as a “Neutral.” The predicted price for XFOR in the upcoming period, according to B. Riley Securities is $1 based on the research report published on December 12, 2023 of the previous year 2023.
B. Riley Securities, on the other hand, stated in their research note that they expect to see XFOR reach a price target of $3. The rating they have provided for XFOR stocks is “Buy” according to the report published on August 30th, 2023.
Cantor Fitzgerald gave a rating of “Overweight” to XFOR, setting the target price at $3 in the report published on December 22nd of the previous year.
XFOR Trading at -42.61% from the 50-Day Moving Average
After a stumble in the market that brought XFOR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -83.95% of loss for the given period.
Volatility was left at 10.30%, however, over the last 30 days, the volatility rate increased by 7.45%, as shares sank -41.36% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -55.13% lower at present.
During the last 5 trading sessions, XFOR fell by -13.17%, which changed the moving average for the period of 200-days by -76.31% in comparison to the 20-day moving average, which settled at $0.3342. In addition, X4 Pharmaceuticals Inc saw -64.99% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at XFOR starting from Baldry Mark, who purchase 21,646 shares at the price of $0.68 back on May 17 ’24. After this action, Baldry Mark now owns 115,769 shares of X4 Pharmaceuticals Inc, valued at $14,654 using the latest closing price.
Baldry Mark, the Chief Commercial Officer of X4 Pharmaceuticals Inc, purchase 13,404 shares at $0.34 during a trade that took place back on Nov 15 ’24, which means that Baldry Mark is holding 129,173 shares at $4,598 based on the most recent closing price.
Stock Fundamentals for XFOR
Current profitability levels for the company are sitting at:
- -6.19 for the present operating margin
- 0.85 for the gross margin
The net margin for X4 Pharmaceuticals Inc stands at -4.01. The total capital return value is set at -0.17. Equity return is now at value -26.35, with -9.54 for asset returns.
Based on X4 Pharmaceuticals Inc (XFOR), the company’s capital structure generated 0.57 points at debt to capital in total, while cash flow to debt ratio is standing at -1.61. The debt to equity ratio resting at 1.31. The interest coverage ratio of the stock is -3.1.
Currently, EBITDA for the company is -107.1 million with net debt to EBITDA at 0.14. When we switch over and look at the enterprise to sales, we see a ratio of 5.83. The receivables turnover for the company is -0.93for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.89.
Conclusion
In summary, X4 Pharmaceuticals Inc (XFOR) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
